Biostage (OTCMKTS:BSTG – Get Free Report) and Haemonetics (NYSE:HAE – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.
Profitability
This table compares Biostage and Haemonetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biostage | N/A | N/A | -174.43% |
| Haemonetics | 11.21% | 22.49% | 9.38% |
Valuation and Earnings
This table compares Biostage and Haemonetics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biostage | N/A | N/A | -$6.07 million | ($0.58) | -7.67 |
| Haemonetics | $1.17 billion | 3.84 | $115.40 million | $2.65 | 33.39 |
Analyst Ratings
This is a summary of recent ratings and price targets for Biostage and Haemonetics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biostage | 0 | 0 | 0 | 0 | N/A |
| Haemonetics | 0 | 2 | 4 | 0 | 2.67 |
Haemonetics has a consensus target price of $103.67, suggesting a potential upside of 17.16%. Given Haemonetics’ higher possible upside, analysts plainly believe Haemonetics is more favorable than Biostage.
Volatility & Risk
Biostage has a beta of -1.02, meaning that its share price is 202% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.
Insider & Institutional Ownership
99.9% of Haemonetics shares are owned by institutional investors. 15.3% of Biostage shares are owned by insiders. Comparatively, 1.8% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Haemonetics beats Biostage on 11 of the 12 factors compared between the two stocks.
About Biostage
Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.
About Haemonetics
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Biostage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage and related companies with MarketBeat.com's FREE daily email newsletter.
